CBIO vs DMAC: stock comparison and AI forecast
Gyre Therapeutics, Inc. (CBIO) and Diamedica Therapeutics Inc. (DMAC) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CBIO Gyre Therapeutics, Inc.
- Market Cap
- $559M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
DMAC Diamedica Therapeutics Inc.
- Price
- $10.00 +60.0% · 6M
- Market Cap
- $539M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- CBIO and DMAC have similar market capitalizations ($559M and $539M).
- CBIO carries 0.32 times debt per unit of equity, against 0.17 times for DMAC.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CBIO | DMAC |
|---|---|---|
| Market Cap | $559M | $539M |
| P/B Ratio | 5.18x | 14.07x |
| EPS | $-0.10 | – |
| Book Value/Share | $2.52 | $0.71 |
| Revenue/Share | $2.81 | – |
| FCF/Share | $-0.37 | $-0.58 |
Profitability & Margins
| Metric | CBIO | DMAC |
|---|---|---|
| ROE | – | -97.9% |
| ROA | – | -83.4% |
| ROIC | -9.8% | -102.1% |
| Gross Margin | 94.3% | – |
| Operating Margin | -13.9% | – |
| EBT Margin | -13.4% | – |
| Tax Rate | -21.4% | -0.1% |
Financial Health
| Metric | CBIO | DMAC |
|---|---|---|
| Current Ratio | 4.26x | 6.72x |
| Quick Ratio | 3.86x | – |
| D/E Ratio | 0.32x | 0.17x |
| Financial Leverage | 1.85x | 1.17x |
| Interest Coverage | -19.4x | -2134.0x |
| Working Capital | $93M | $38M |
Cash Flow
| Metric | CBIO | DMAC |
|---|---|---|
| Operating Cash Flow | -$14M | -$32M |
| Free Cash Flow | -$16M | -$32M |
| Capital Spending | -$1M | -$30K |
| OCF Growth YoY | -1663.9% | – |
| FCF/Sales | -13.1% | – |
| CapEx/Sales | 1.0% | – |
Operational Efficiency
| Metric | CBIO | DMAC |
|---|---|---|
| Asset Turnover | 0.60x | – |
| Receivables Turnover | 4.3x | – |
| Inventory Turnover | 0.6x | – |
| Fixed Assets Turnover | 4.4x | – |
| Days Sales Outstanding | 84 days | – |
| Days Inventory | 613 days | – |
| Payables Period | 66 days | – |
| Cash Conversion Cycle | 631 days | – |
Income Statement
| Metric | CBIO | DMAC |
|---|---|---|
| Total Revenue | $120M | – |
| Operating Income | -$17M | -$39M |
| Net Income | – | -$38M |
| R&D Expense | $17M | $29M |
| SG&A Expense | $96M | – |
| Cost of Goods Sold | $7M | – |
Dividend & Shareholder Information
| Metric | CBIO | DMAC |
|---|---|---|
| Shares Outstanding | 43M | 54M |
| EPS Growth | -350.0% | – |
CBIO vs DMAC: stock comparison and AI forecast
Which is bigger, CBIO or DMAC?
CBIO and DMAC have similar market capitalizations ($559M and $539M).
Which one does Intratio's AI model rank higher, CBIO or DMAC?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.